A CD47 antibody with minimized erythrocyte and thrombocyte toxicities
Authors:
Open Access
- 26 November 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1686180
Abstract
Introduction: Blockade of the CD47/SIRPa axis has emerged as a promising approach to enhance macrophage-mediated anti-tumor activities in cancer immunotherapy. However, the clinical application of early CD47 antibodies has been associated with significant hematotoxicities, including hemagglutination, anemia, and thrombopenia. Although several CD47 antibodies have generally avoided hemagglutination, anemia, and thrombopenia remain, potentially mediated by enhanced phagocytosis of erythrocytes and thrombocytes. Methods: 1B2–10 is a humanized CD47-neutralizing antibody generated by mouse immunization and phage display technology. Its efficacy and safety were evaluated using in vitro assays, tumor xenograft models, and studies in cynomolgus monkeys. In silico modeling and mutagenesis analyses were performed to identify the 1B2-10 binding epitopes. Results: In vitro , 1B2–10 exhibited minimized binding to erythrocytes and thrombocytes, did not induce hemagglutination, and reduced erythrocyte phagocytosis. It enhanced macrophage-mediated phagocytosis of tumor cells and showed potent antitumor effects as a monotherapy or in combination with a PD-1 antibody in tumor models. In cynomolgus monkeys, single doses of 1B2–10 at 120 mg/kg and repeated doses at 100 mg/kg were well-tolerated, with no significant hematological toxicities observed. In silico studies revealed the molecular basis for reduced erythrocyte binding, demonstrating that two critical N-linked glycans sterically masked epitopes. Discussion: These findings suggest that 1B2-10 demonstrates a favorable efficacy and safety profile, indicating great therapeutic potential for cancer. Based on these studies, 1B2–10 has been renamed as DS003 and is currently advancing through Phase I clinical trials in China to further evaluate its safety profile and preliminary efficacy in human subjects.Keywords
This publication has 50 references indexed in Scilit:
- Engineered CD47 protects T cells for enhanced antitumour immunityNature, 2024
- Emerging phagocytosis checkpoints in cancer immunotherapySignal Transduction and Targeted Therapy, 2023
- 617O Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical resultsAnnals of Oncology, 2022
- Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylationCell Reports, 2021
- The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutinationSignal Transduction and Targeted Therapy, 2020
- Phagocytosis checkpoints as new targets for cancer immunotherapyNature Reviews Cancer, 2019
- SIRPα–CD47 Immune Checkpoint Blockade in Anticancer TherapyTrends in Immunology, 2018
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumorsNature Medicine, 2015
- Cloning Single-Chain Antibody Fragments (ScFv) from Hyrbidoma Cells2012
- Binding of blood proteins to carbon nanotubes reduces cytotoxicityProceedings of the National Academy of Sciences, 2011